Device designed to treat a leading cause of blindness

February 29, 2012 By Alexis Blue
Device designed to treat a leading cause of blindness
A new investigational device, invented by a UA professor, could dramatically change the way the degenerative disease is treated.

(Medical Xpress) -- Every year, more than 200,000 people in the U.S. are diagnosed with Wet Age-Related Macular Degeneration, a leading cause of blindness in Americans age 60 or older. There is no known cure for the disease, which can lead to partial or complete vision loss.

But a new investigational device, invented by a University of Arizona professor, could dramatically change the way the is treated.

Wet Age-Related , or Wet AMD, occurs when begin to grow behind the eye's macula, located in the center of the retina, and leak fluid that causes the macula to shift from its normal position and become damaged. It is more serious than the more common Dry , which occurs when in the macula break down, blurring .

One of the most common treatments for Wet AMD is repeated injections into the eye of anti-VGEF (anti-Vascular Endothelial Growth Factor) drugs, designed to slow the growth of abnormal .

But those injections, administered as often as once a month for life, can be uncomfortable for patients and are not effective for everyone, said Russell Hamilton, professor and head of the physics section of the UA department of oncology.

So Hamilton set out to find a less invasive way to treat patients that would reduce, or perhaps altogether eliminate, the need for repeated anti-VGEF injections.

His investigational device, which is now in the early stages of human study, is designed to deliver targeted radiation to blood vessel leaks via a small radioactive seed inserted behind the eye. The idea is that targeted radiation will provide a more long-term solution and help increase the effectiveness of initial anti-VGEF injections.

"When you're diagnosed with Wet AMD, you would have the anti-VGEF injection immediately. We're hoping the radiation will then increase the durability of the treatment, so that after the first month patients won't need to be injected again," said Hamilton, who also is a co-founder of Salutaris Medical Devices Inc., a privately held Tucson company founded to develop an investigational ophthalmic treatment for Wet AMD.

The device, about six inches in length, includes a wire with a curved end, designed to fit around the eye. It is inserted over the top of the eye, through a small incision, and moved toward the back of the eye, where it delivers a dose of radiation to repair troublesome leaks.

Requiring only a small incision, the procedure is minimally invasive and is intended to be done under local anesthesia in approximately 15 minutes in a physician's office or outpatient setting.

Researchers say it could be a safer, simpler alternative to external radiation, which also has been used to treat Wet AMD, and to other investigational treatments that involve penetration of the eye to deliver radiation.

"If this is proven in a larger trial, it's going to be game changing," said Dr. Baldassarre Stea, professor and chairman of the UA department of radiation oncology and co-principal investigator of the device study, along with Dr. Reid Schindler, clinical associate professor in the UA department of ophthalmology and vision science.   

"Not only is it going to be beneficial from an economic point of view, in an era where resources are limited and the injections cost $2,000 a shot, but the quality of life of the patient will also be impacted," Stea said. "You regain your vision better, you don't have to go back and forth to the ophthalmologist every month to get the injection, and you save money and aggravation."

Hamilton said he began working on his device after learning of the successful use of radiation to treat melanoma of the eye.

In January, the results of a Phase 1 study to evaluate the safety of the device were shared during Meeting 2012. Of the six test subjects treated with the device, all saw improvement in vision, none experienced additional and three were able to discontinue their anti-VGEF injections. Furthermore, there were no reported "Serious Adverse Events" or "Unanticipated Adverse Device Effects."

Additional studies are expected to get under way later this year. Stea said if those go well, FDA approval for the device could happen within a few years.

Explore further: Vision loss slowed by encapsulated cell therapy

Related Stories

Vision loss slowed by encapsulated cell therapy

April 7, 2011
( -- A phase 2 clinical trial for the treatment of a severe form of age-related macular degeneration called geographic atrophy (GA) has become the first study to show the benefit of a therapy to slow the progression ...

Report shows risk of blindness halved over last decade

January 19, 2012
Age-related macular degeneration (AMD) is the most frequent cause of blindness in the Western World. A report from the University of Copenhagen and Glostrup Hospital in Denmark published today shows the number of new cases ...

Study shows daily aspirin intake can lead to blindness

October 5, 2011
(Medical Xpress) -- A new study published in Ophthalmology reveals that while taking a daily aspirin may reduce the risks of heart disease and stroke, a disturbing side effect has also been noted to increase the risk of developing ...

Recommended for you

Combination of type 2 diabetes and sleep apnoea indicates eyesight loss within four years

July 4, 2017
Research led by the University of Birmingham has discovered that patients who suffer from both Type 2 diabetes and obstructive sleep apnoea are at greater risk of developing a condition that leads to blindness within an average ...

Nearly 60% of pinkeye patients receive antibiotic eye drops, but they're seldom necessary

June 28, 2017
A new study suggests that most people with acute conjunctivitis, or pinkeye, are getting the wrong treatment.

Magnetic implants used to treat 'dancing eyes'

June 26, 2017
A research team has successfully used magnets implanted behind a person's eyes to treat nystagmus, a condition characterised by involuntary eye movements.

Drug shows promise against vision-robbing disease in seniors

June 21, 2017
An experimental drug is showing promise against an untreatable eye disease that blinds older adults—and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.

Reproducing a retinal disease on a chip

June 15, 2017
Approximately 80% of all sensory input is received via the eyes, so suffering from chronic retinal diseases that lead to blindness causes a significant decrease in the quality of life (QOL). And because retinal diseases are ...

New gene therapy for vision loss proven safe in humans

May 16, 2017
In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to introduce a therapeutic gene into the eye is safe and that it ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.